- Algernon (AGN) has provided an update on its planned Phase 1 clinical human study of AP-188
- Algernon is completing the intravenous formulation that will be used in the study and has retained the Centre for Human Drug Research in the Netherlands
- The company is planning to begin the Phase 1 study in September
- Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the update
- Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.42 per share
Algernon (AGN) has provided an update on its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”).
The company is currently working to complete the intravenous formulation that will be used in the Phase 1 DMT study and has retained the Centre for Human Drug Research and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands, to complete the work.
Algernon plans to begin the Phase 1 study in September of 2022.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the news.
The primary focus of Algernon’s planned Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT. The resulting data will help the company plan its Phase 2 acute stroke and rehabilitation studies.
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug that produces effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.42 per share.
